Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to -$0.28.

  • TScan Therapeutics' EPS (Basic) fell 1200.0% to -$0.28 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.12, marking a year-over-year decrease of 1666.67%. This contributed to the annual value of -$1.13 for FY2024, which is 1700.38% up from last year.
  • TScan Therapeutics' EPS (Basic) amounted to -$0.28 in Q3 2025, which was down 1200.0% from -$0.28 recorded in Q2 2025.
  • In the past 5 years, TScan Therapeutics' EPS (Basic) ranged from a high of $0.38 in Q4 2021 and a low of -$7.69 during Q2 2021
  • Moreover, its 5-year median value for EPS (Basic) was -$0.32 (2024), whereas its average is -$1.11.
  • As far as peak fluctuations go, TScan Therapeutics' EPS (Basic) soared by 10470.3% in 2021, and later plummeted by 30263.16% in 2022.
  • Over the past 5 years, TScan Therapeutics' EPS (Basic) (Quarter) stood at $0.38 in 2021, then plummeted by 302.63% to -$0.77 in 2022, then skyrocketed by 85.71% to -$0.11 in 2023, then crashed by 181.83% to -$0.31 in 2024, then grew by 9.68% to -$0.28 in 2025.
  • Its last three reported values are -$0.28 in Q3 2025, -$0.28 for Q2 2025, and -$0.26 during Q1 2025.